PALO ALTO, Calif.--(BUSINESS WIRE)--Varian, a Siemens Healthineers company, announced 510(k) clearance from the U.S. Food and Drug Administration allowing sale of its RapidArc Dynamic solution,* a ground-breaking technology leveraging advanced algorithms to revolutionize treatment planning to shorten the time between consultation to treatment.
Radiation therapy is part of the standard of care for roughly half of all cancer patients and has made significant strides over the years to minimize dose delivery to organs at risk. Precision in radiation therapy is crucial to improving post-treatment quality of life and reducing the risk of long-term complications as cancer patients live longer. For example, during treatment for breast or lung cancer, each gray (Gy) – a measure of radiation dose – that reaches the heart increases the relative risk of cardiac morbidity by 5%-7% and increases cardiac mortality by 1%-2%.123 RapidArc Dynamic introduces advanced precision and control capabilities that have the potential to significantly reduce these risks in a single solution, while enabling efficiency.
Early research has showcased the potential of RapidArc Dynamic, available as an optional feature for the latest version of Eclipse treatment planning software on the TrueBeam 4.1 radiotherapy delivery platform, to deliver significant benefits by reducing the dose to organs at risk by up to 50% and accelerating plan optimization and dose calculation by up to 70%. Additionally, early experiences showed that the number of treatment arcs could be reduced by as much as half.
“RapidArc Dynamic is the latest example of Varian’s sustained investment in innovation, and ushers in a radical transformation in radiotherapy planning and delivery designed to bring flexibility to care teams using for arc therapy,” said Sasa Mutic, PhD, President, Radiation Oncology Solutions for Varian. “The increased efficiency of RapidArc Dynamic to optimize plans has the potential to help decrease the time between diagnosis and treatment. Combined with significant radiation dose improvements, this is a major step in our field.”
RapidArc Dynamic offers robust features designed to give care teams greater freedom and control in treatment planning and delivery:
- Next-generation algorithms empower clinicians to plan and deliver treatments more quickly and effectively, and handle a high volume of cases without compromising on quality in ways that were not possible on previous systems.
- Dynamic collimator can be adjusted in real time, and the gantry can be strategically paused during arc rotation to provide increased control to help ensure consistent and optimal dose delivery, combining the precision of modulated ports and arc therapy in a single treatment field.
- Simplifies workflows with built-in tools such as Auto-Skin Flash, which automates and simplifies a multi-step process, and streamlines workflow for advanced features including Multi-Criteria Optimization (MCO), RapidPlan, and clinical goals templates within the Eclipse treatment planning system.
“RapidArc Dynamic represents a powerful new solution for personalizing treatment planning and delivery with the potential to further reduce doses to organs at risk which can help reduce toxicities without disrupting treatment workflow,” Sushil Beriwal, MD, Vice President, Digital Oncology, Medical Affairs for Varian. “This new flexibility aims to help care teams reach new milestones in improving treatment outcomes.”
* All the FDA 510(k) clearances are in place to support the RapidArc Dynamic solution.
CE Marked. 510(k) cleared. Not available for sale in all markets and no guarantee of commercialization or feature availability.
© 2024 Varian Medical Systems, Inc. All rights reserved. All trademarks are the property of their respective owners.
About Varian
At Varian, a Siemens Healthineers company, we envision a world without fear of cancer. For more than 75 years, Varian has developed, built, and delivered innovative technologies and solutions that help care providers around the globe treat millions of patients each year. Today, as a Siemens Healthineers company, we support every step of the cancer care journey – from screening to survivorship. From advanced imaging and radiation therapy to comprehensive software and services, to interventional radiology, we are harnessing the power of our perspective while also pursuing clinical research to create a more efficient, and more personalized care pathway. Because, for cancer patients everywhere, their fight is our fight. For more information, visit http://www.varian.com.
| _______________________________ |
1 Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Brønnum D, Correa C, Cutter D, Gagliardi G, Gigante B, Jensen MB, Nisbet A, Peto R, Rahimi K, Taylor C, Hall P. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013 Mar 14;368(11):987-98. doi: 10.1056/NEJMoa1209825. PMID: 23484825. |
2 Atkins KM, Chaunzwa TL, Lamba N, et al. Association of Left Anterior Descending Coronary Artery Radiation Dose With Major Adverse Cardiac Events and Mortality in Patients With Non–Small Cell Lung Cancer. JAMA Oncol. 2021;7(2):206–219. doi:10.1001/jamaoncol.2020.6332 |
3 Atkins, K, Rawal, B, Chaunzwa, T. et al. Cardiac Radiation Dose, Cardiac Disease, and Mortality in Patients With Lung Cancer. JACC. 2019 Jun, 73 (23) 2976–2987. |
